Viimased lisandused - Age-Related Macular Degeneration - Dry
|
Reticular pseudodrusenvaatamisi: 103veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 108veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 106veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 94veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 96veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 88veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 108veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 105veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 98veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 107veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 93veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 98veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 95veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 99veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 100veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 111veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 105veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 93veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 94veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 87veebr 23, 2025
|
|
Reticular pseudodrusenvaatamisi: 90veebr 23, 2025
|
|
54 year old female with a lot of drusenvaatamisi: 89VA 20/12 OD, 20/16 OS - no symptomsdets 21, 2024
|
|
54 year old female with a lot of drusenvaatamisi: 86VA 20/12 OD, 20/16 OS - no symptomsdets 21, 2024
|
|
54 year old female with a lot of drusenvaatamisi: 88VA 20/12 OD, 20/16 OS - no symptomsdets 21, 2024
|
|
54 year old female with a lot of drusenvaatamisi: 83VA 20/12 OD, 20/16 OS - no symptomsdets 21, 2024
|
|
54 year old female with a lot of drusenvaatamisi: 102VA 20/12 OD, 20/16 OS - no symptomsdets 21, 2024
|
|
54 year old female with a lot of drusenvaatamisi: 99VA 20/12 OD, 20/16 OS - no symptomsdets 21, 2024
|
|
54 year old female with a lot of drusenvaatamisi: 92VA 20/12 OD, 20/16 OS - no symptomsdets 21, 2024
|
|
54 year old female with a lot of drusenvaatamisi: 92VA 20/12 OD, 20/16 OS - no symptomsdets 21, 2024
|
|
Large Hyper-reflective drusen in age-related macular degenerationvaatamisi: 14269 year old healthy woman with 20/20 vision and no visual complaintssept 22, 2023
|
|
Large Hyper-reflective drusen in age-related macular degenerationvaatamisi: 14369 year old healthy woman with 20/20 vision and no visual complaintssept 22, 2023
|
|
Large Hyper-reflective drusen in age-related macular degenerationvaatamisi: 13369 year old healthy woman with 20/20 vision and no visual complaintssept 22, 2023
|
|
Large Hyper-reflective drusen in age-related macular degenerationvaatamisi: 12569 year old healthy woman with 20/20 vision and no visual complaintssept 22, 2023
|
|
Large Hyper-reflective drusen in age-related macular degenerationvaatamisi: 14469 year old healthy woman with 20/20 vision and no visual complaintssept 22, 2023
|
|
Large Hyper-reflective drusen in age-related macular degenerationvaatamisi: 14469 year old healthy woman with 20/20 vision and no visual complaintssept 22, 2023
|
|
Large Hyper-reflective drusen in age-related macular degenerationvaatamisi: 13669 year old healthy woman with 20/20 vision and no visual complaintssept 22, 2023
|
|
Large Hyper-reflective drusen in age-related macular degenerationvaatamisi: 12769 year old healthy woman with 20/20 vision and no visual complaintssept 22, 2023
|
|
Large Hyper-reflective drusen in age-related macular degenerationvaatamisi: 13869 year old healthy woman with 20/20 vision and no visual complaintssept 22, 2023
|
|
Dry Macular Degeneration with Pseudodrusen and vitelliform lesionvaatamisi: 12180 year old female with 20/50 vision in both eyes. Mild blurringsept 17, 2023
|
|
Dry Macular Degeneration with Pseudodrusen and vitelliform lesionvaatamisi: 11380 year old female with 20/50 vision in both eyes. Mild blurringsept 17, 2023
|
|
Dry Macular Degeneration with Pseudodrusen and vitelliform lesionvaatamisi: 10480 year old female with 20/50 vision in both eyes. Mild blurringsept 17, 2023
|
|
Dry Macular Degeneration with Pseudodrusen and vitelliform lesionvaatamisi: 10280 year old female with 20/50 vision in both eyes. Mild blurringsept 17, 2023
|
|
Dry Macular Degeneration with Pseudodrusen and vitelliform lesionvaatamisi: 11080 year old female with 20/50 vision in both eyes. Mild blurringsept 17, 2023
|
|
Dry Macular Degeneration with Pseudodrusen and vitelliform lesionvaatamisi: 13080 year old female with 20/50 vision in both eyes. Mild blurringsept 17, 2023
|
|
Dry Macular Degeneration with Pseudodrusen and vitelliform lesionvaatamisi: 13080 year old female with 20/50 vision in both eyes. Mild blurringsept 17, 2023
|
|
Dry Macular Degeneration with Pseudodrusen and vitelliform lesionvaatamisi: 11380 year old female with 20/50 vision in both eyes. Mild blurringsept 17, 2023
|
|
Dry Macular Degeneration with Pseudodrusen and vitelliform lesionvaatamisi: 13080 year old female with 20/50 vision in both eyes. Mild blurringsept 17, 2023
|
|
Optic Disc Melanocytoma - Atypicalvaatamisi: 24945 year old female with normal vision and optic nerve lesion in the left eye. VA 20/16 OU. Extensive testing was normal including brain and orbit MRI. The lesion has been stable for 5 years.aug 17, 2022
|
|
Optic Disc Melanocytoma - Atypicalvaatamisi: 22145 year old female with normal vision and optic nerve lesion in the left eye. VA 20/16 OU. Extensive testing was normal including brain and orbit MRI. The lesion has been stable for 5 years.aug 17, 2022
|
|
Optic Disc Melanocytoma - Atypicalvaatamisi: 22045 year old female with normal vision and optic nerve lesion in the left eye. VA 20/16 OU. Extensive testing was normal including brain and orbit MRI. The lesion has been stable for 5 years.aug 17, 2022
|
|
Optic Disc Melanocytoma - Atypicalvaatamisi: 22445 year old female with normal vision and optic nerve lesion in the left eye. VA 20/16 OU. Extensive testing was normal including brain and orbit MRI. The lesion has been stable for 5 years.aug 17, 2022
|
|
Optic Disc Melanocytoma - Atypicalvaatamisi: 21845 year old female with normal vision and optic nerve lesion in the left eye. VA 20/16 OU. Extensive testing was normal including brain and orbit MRI. The lesion has been stable for 5 years.aug 17, 2022
|
|
Optic Disc Melanocytoma - Atypicalvaatamisi: 22745 year old female with normal vision and optic nerve lesion in the left eye. VA 20/16 OU. Extensive testing was normal including brain and orbit MRI. The lesion has been stable for 5 years.aug 17, 2022
|
|
Optic Disc Melanocytoma - Atypicalvaatamisi: 22645 year old female with normal vision and optic nerve lesion in the left eye. VA 20/16 OU. Extensive testing was normal including brain and orbit MRI. The lesion has been stable for 5 years.aug 17, 2022
|
|
Optic Disc Melanocytoma - Atypicalvaatamisi: 22445 year old female with normal vision and optic nerve lesion in the left eye. VA 20/16 OU. Extensive testing was normal including brain and orbit MRI. The lesion has been stable for 5 years.aug 17, 2022
|
|
Optic Disc Melanocytoma - Atypicalvaatamisi: 24145 year old female with normal vision and optic nerve lesion in the left eye. VA 20/16 OU. Extensive testing was normal including brain and orbit MRI. The lesion has been stable for 5 years.aug 17, 2022
|
|
Optic Disc Melanocytoma - Atypicalvaatamisi: 23145 year old female with normal vision and optic nerve lesion in the left eye. VA 20/16 OU. Extensive testing was normal including brain and orbit MRI. The lesion has been stable for 5 years.aug 17, 2022
|
|
Optic Disc Melanocytoma - Atypicalvaatamisi: 25545 year old female with normal vision and optic nerve lesion in the left eye. VA 20/16 OU. Extensive testing was normal including brain and orbit MRI. The lesion has been stable for 5 years.aug 17, 2022
|
|
Dry AMD - Pigment - AREDS risk score of 4vaatamisi: 23665 year old woman with 20/32 vision. A little blurred. Pigment and large drusen in each eye. AREDS risk score of four.aug 17, 2022
|
|
Dry AMD - Pigment - AREDS risk score of 4vaatamisi: 22265 year old woman with 20/32 vision. A little blurred. Pigment and large drusen in each eye. AREDS risk score of four.aug 17, 2022
|
|
Dry AMD - Pigment - AREDS risk score of 4vaatamisi: 22565 year old woman with 20/32 vision. A little blurred. Pigment and large drusen in each eye. AREDS risk score of four.aug 17, 2022
|
|
Dry AMD - Pigment - AREDS risk score of 4vaatamisi: 23265 year old woman with 20/32 vision. A little blurred. Pigment and large drusen in each eye. AREDS risk score of four.aug 17, 2022
|
|
Dry AMD - Pigment - AREDS risk score of 4vaatamisi: 22065 year old woman with 20/32 vision. A little blurred. Pigment and large drusen in each eye. AREDS risk score of four.aug 17, 2022
|
|
Dry AMD - Pigment - AREDS risk score of 4vaatamisi: 22165 year old woman with 20/32 vision. A little blurred. Pigment and large drusen in each eye. AREDS risk score of four.aug 17, 2022
|
|
Dry AMD - Pigment - AREDS risk score of 4vaatamisi: 20865 year old woman with 20/32 vision. A little blurred. Pigment and large drusen in each eye. AREDS risk score of four.aug 17, 2022
|
|
Dry AMD - Pigment - AREDS risk score of 4vaatamisi: 23465 year old woman with 20/32 vision. A little blurred. Pigment and large drusen in each eye. AREDS risk score of four.aug 17, 2022
|
|
Dry AMD - Pigment - AREDS risk score of 4vaatamisi: 20565 year old woman with 20/32 vision. A little blurred. Pigment and large drusen in each eye. AREDS risk score of four.aug 17, 2022
|
|
Dry AMD - Pigment - AREDS risk score of 4vaatamisi: 19665 year old woman with 20/32 vision. A little blurred. Pigment and large drusen in each eye. AREDS risk score of four.aug 17, 2022
|
|
Soft Drusenvaatamisi: 24563 year old female with 20/16 vision both eyesokt 17, 2021
|
|
Soft Drusenvaatamisi: 26463 year old female with 20/16 vision both eyesokt 17, 2021
|
|
Soft Drusenvaatamisi: 24663 year old female with 20/16 vision both eyesokt 17, 2021
|
|
Soft Drusenvaatamisi: 24063 year old female with 20/16 vision both eyesokt 17, 2021
|
|
Soft Drusenvaatamisi: 24263 year old female with 20/16 vision both eyesokt 17, 2021
|
|
Soft Drusenvaatamisi: 27863 year old female with 20/16 vision both eyesokt 17, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 25779 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 23479 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 24479 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 24979 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 25679 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 25079 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 27579 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 25879 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 25079 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 28779 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 26979 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 23679 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 26279 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 24879 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 22379 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 25279 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 24479 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 26779 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 26779 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 27079 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 22079 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 24079 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 26579 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 26179 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 25979 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
Age-related macular degeneration - Geographic Atrophy - Intermittent CME left eye from CRVO, Anemia, Diabetesvaatamisi: 28679 year old female - 3 years post CRVO in the left eye (20/32 VA) with intermittent CME. Left eye is the better eye. Vision is stable since 2 years ago
PMHx: Type II DM x 20 years, Chronic Anemia, Hyperlipidemia
VA 20/200 OD, 20/50 OS (usually 20/40)okt 16, 2021
|
|
|
|
